Additionally, this study showed that ANRIL regulated the expression of the adiponectin receptor and its downstream factors adenosine monophosphate-activated protein kinase (AMPK)/sirtuin 1 (SIRT1), thereby modulating disease progression by regulating glucose metabolism 108; these findings suggest that ANRIL represents both a potential candidate for AML diagnosis and a therapeutic target. This evidence concerns the gene CDKN2B-AS1 and acute myeloid leukemia.